Caustic Esophageal Burns in Children and High Doses of Methylprednisolone
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02002078 |
Recruitment Status :
Completed
First Posted : December 5, 2013
Last Update Posted : December 5, 2013
|
Sponsor:
Sisli Hamidiye Etfal Training and Research Hospital
Information provided by (Responsible Party):
Merve Usta, Sisli Hamidiye Etfal Training and Research Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Corrosive substance ingestion in childhood is a public health issue in developing countries and several management protocols were proposed to prevent esophageal strictures. The role of corticosteroids in preventing corrosive-induced strictures is controversial. The investigators' aim is to study the influence of high doses of corticosteroids to prevent esophageal strictures.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Esophageal Diseases | Drug: methylprednisolon | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 83 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Single (Care Provider) |
Primary Purpose: | Prevention |
Official Title: | High Doses of Methylprednisolone in the Management of Caustic Esophageal Burns in Children |
Study Start Date : | February 2007 |
Actual Primary Completion Date : | December 2008 |
Actual Study Completion Date : | December 2008 |
Resource links provided by the National Library of Medicine

Arm | Intervention/treatment |
---|---|
No Intervention: Methylprednisolone, caustic burns |
Drug: methylprednisolon |
Primary Outcome Measures :
- Evaluation of stricture development in children with caustic esophageal burns after high doses of methylprednisolone [ Time Frame: three years ]stricture development was evaluated with endoscopic examination and upper gastrointestinal system series with barium swallow
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Months to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
-Corrosive substance ingested children with grade IIb esophageal burn
Exclusion Criteria:
- Caustic substance ingested chldren grade I, IIa and grade III esophageal burns
- Caustic subtance ingested children with signs of perforation, mediastinitis, peritonitis, sespis
- Caustic substance ingested children with any chronic disease
No Contacts or Locations Provided
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Merve Usta, DR, Sisli Hamidiye Etfal Training and Research Hospital |
ClinicalTrials.gov Identifier: | NCT02002078 |
Other Study ID Numbers: |
ClinicalTrials.gov |
First Posted: | December 5, 2013 Key Record Dates |
Last Update Posted: | December 5, 2013 |
Last Verified: | November 2013 |
Keywords provided by Merve Usta, Sisli Hamidiye Etfal Training and Research Hospital:
caustic corticosteroid therapy stricture children |
Additional relevant MeSH terms:
Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Anti-Inflammatory Agents Antiemetics |
Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Neuroprotective Agents Protective Agents Antineoplastic Agents, Hormonal Antineoplastic Agents |